Endocardial Vs Epicardial Ablation for Recurrent Paroxysmal AF

Recurrent Paroxysmal Atrial Fibrillation Despite Prior Pulmonary Vein Isolation Clinical Trial

— REPEAL-AF  

Official title:

Comparison of Repeat Endocardial PVI Vs Epicardial Posterior Wall Isolation and LAA Clip Plus PVI for Recurrent Atrial Fibrillation After Prior PVI

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04506814
• Other study ID #: UR Re-ablation Paroxysmal AF
• Status: Withdrawn
• Phase: N/A
• Start date: January 2025
• Est. completion date: January 2028

Study information

• Verified date: November 2023
• Source: University of Rochester
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is no current accepted and predictably effective ablative therapy for patients with recurrent paroxysmal atrial fibrillation after prior pulmonary vein isolation (PVI). This study will compare redo PVI with hybrid epicardial ablation incorporating posterior wall isolation and LAA clip, and redo PVI.

Description:

In these redo ablation patients, the ideal re-ablation strategy is unknown and many techniques have been proposed but there is no consensus nor strong clinical trial data. This treatment gap prompted the development of a combined minimally invasive epicardial and endocardial ablation ("Convergent") procedure. During the last decade, this "hybrid" approach has garnered increasing acceptance in clinical practice, with several reports of promising antiarrhythmic outcomes in challenging disease states, as well as modifications to maximize safety and clinical outcomes. One key aspect of this approach is that it targets key drivers of AF including the PVs but also the left atrial posterior wall (LAPW), combining endocardial and epicardial energy delivery. The LAPW (or "PV myocardium") shares similar embryological origins and electrophysiological properties with the PVs, is predisposed to develop fibrosis, and thus recognized as an important source of AF. Recently, the CONVERGE randomized clinical trial demonstrated superiority of this hybrid approach compared to PVI in patients with persistent AF. The left atrial appendage (LAA) has also been designated as a potential important trigger site of AF, and if isolated, may result in improved post-ablation AF outcomes. Although catheter-based isolation is controversial due to the potential to increase the risk of stroke, surgical exclusion of the LAA by placement of an occlusive clip has been suggested to be both antiarrhythmic and anti-thrombotic. Thus it is proposed in this trial to incorporate the LAA clip within the hybrid procedure. Given the sheer volume of patients undergoing ablation of AF and the predictable necessity to perform repeat ablation procedures on a portion of these patients, the need for a proven redo ablation strategy is self-evident. The investigators thus propose a randomized clinical trial to determine if there is incremental efficacy by performing LAPW/LAA isolation via a hybrid approach in comparison to the conventional redo PVI alone in patients with paroxysmal AF.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2028
• Est. primary completion date: January 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria

1. Age > 18 years

2. Symptomatic paroxysmal AF despite prior 1 or 2 PVI procedures within past 10 years (paroxysmal AF lasting up to 7 days before spontaneous termination)

3. Eligible for referral for re-ablation based on current guidelines

4. LA diameter < 6.0 cms on transthoracic echo

5. Willingness to comply with post-procedural follow-up requirements and to sign informed consent Exclusion Criteria

1. Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus, contraindication to anticoagulation)

2. Prior history of open heart surgery

3. Prior history of pericarditis or pericardiocentesis

4. Prior history of stroke/TIA/systemic embolism

5. NYHA class IV congestive heart failure or LVEF < 25%

6. Persistent or longstanding persistent AF (duration > 1 year)

7. Coronary revascularization or valve surgery within 3 months

8. Prior valve surgery using a mechanical prosthesis

9. An estimated glomerular filtration rate (eGFR) < 45mL/min/1.73m2, using the MDRD calculation

10. Life expectancy <1 year for any medical condition

11. AF due to reversible cause e.g. hyperthyroid state

12. Women who are pregnant or plan to become pregnant during the course of the trial** Note: Women of childbearing potential must have a negative pregnancy test within 7 days prior to randomization.

13. Participation in other clinical trials that will affect the objectives of this study

14. History of non-compliance to medical therapy

15. Inability or unwillingness to provide informed consent

16. Resides at such a distance from the enrolling site so travel to follow-up visits would be unusually difficult

17. Does not anticipate residing in the vicinity of the enrolling site for the duration of the trial

Related Conditions & MeSH terms

• Atrial Fibrillation
• Recurrence
• Recurrent Paroxysmal Atrial Fibrillation Despite Prior Pulmonary Vein Isolation

Intervention

Device:
• Endocardial PVI
Catheter based PVI
• Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI
Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI

Locations

Country	Name	City	State
United States	University of Rochester	Short Hills	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
University of Rochester	Meshalkin Research Institute of Pathology of Circulation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Atrial fibrillation > 30 secs	Based on serial 7-day Holter recordings	At 1 year